 |
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312-773X (Online)
Issue: Volume 15, book 1, 2009
Subject Collection: Medicine
Page: 46 - 49
DOI: 10.5272/jimab.1512009_46
Online date:Aug 5, 2009
SINGLE- AGENT CAPECITABINE AS FIRST- LINE TREATMENT
OF PATIENTS WITH METASTATIC COLORECTAL CANCER
Deyan Davidov
Department of Chemotherapy, Oncological Center, Medical University,
Pleven, Bulgaria
SUMMARY: Background: Capecitabine
is an oral fluoropyrimidine carbamate that is at least as effective than
Fluorouracil / Leucovorin as first- line treatment for patients with metastatic
colorectal cancer /CRC/. Aim: The aim of this study was
to evaluate the efficacy and toxicity of single- agent Capecitabine as
first- line therapy in patients with metastatic CRC. Methods: In the period 2007- 2009 17 consecutive patients with /CRC/ entered
the study. The treatment schedule consists of Capecitabine 1250 mg/m2
p.o. twice daily for 14 days with a 7- day rest period. Results: Overall response rate was 23,6% with one complete remission. Median survival
was 12,4 months. Nausea, vomiting and diarrhea were the most common side
effects. Conclusions: That data suggest that single-
agent Capecitabine will offer opportunity to treat patients with advanced
/CRC/.
Key words: Metastatic colorectal cancer, First- line
therapy, Single- agent Capecitabine, Survival.
Page: 46-49; FULL TEXT PDF (124 KB)